What is the key to a robust immunity against SARS-CoV-2? According to a study recently published in The New England Journal of Medicine, it could be a previous SARS infection—more specifically, the one that spread across 29 countries between 2002 and 2004—plus vaccination.
According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.
Pfizer Inc. and BioNTech’s Covid-19 vaccine appeared to lose only a small bit of effectiveness against an engineered virus with three key mutations from the new coronavirus variant found in South Africa, according to a laboratory study conducted by the U.S. drugmaker.
Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19.
A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
In recent weeks, the threat to South Korea from Middle East Respiratory Syndrome, better known as MERS, has exploded. Over the last 18 months or so, Ebola has hit West […]
